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Interleukin (IL)-21 is a newly described cytokine that is
produced by activated T cells and displays structural
homology to IL-4 and IL-15.We here analyzed the role
of IL-21 in dendritic cell (DC)-induced,Tcell-mediated
contact hypersensitivity (CHS) in vivo and on T cell ac-
tivation and unspeci¢c mixed lymphocyte reaction in
vitro. By PCR, we demonstrate here constitutive expres-
sion of the speci¢c IL-21 receptor and the common
c-chain in DC, which together are able to mediate IL-
21 signaling. Short-time incubation of in vitro generated
DC with IL-21 signi¢cantly reduced their potential to
induce an antigen-speci¢c CD8þ T cell proliferation.
Interestingly, 2h incubation of these DC with IL-21
before injection completely inhibited the potential of
these DC to induce a CHS reaction to the hapten £uor-
escein 5-isothiocyanate in vivo. Mice injected with IL-
21-treated DC even failed to mount a CHS response
after repetitive injection of non-IL-21-treated DC 2
weeks later, suggesting that an antigen-speci¢c unre-
sponsiveness can be induced by IL-21-treated DC. Our
data demonstrate that IL-21 is a new modulator of DC^
T cell interaction with the potential to induce DC-
mediated antigen-speci¢c tolerance. Key words: dendritic
cells/cytokines/in£ammation/T cells. J Invest Dermatol 121:
1379 ^1382, 2003
D
endritic cells (DC) are professional antigen-pre-
senting cells that initiate T cell-mediated immune
responses. The capacity of mature DC to prime
na|«ve T cells and promote their di¡erentiation is
not only attributed to upregulation of costimula-
tory and adhesion molecules but also to the ability to secrete
cytokines. In contrast, polarizing signals from the microenviron-
ment or fromT cells during DC^T cell interaction directly shape
the outcome of an immune response during antigen presentation
( Jonuleit et al, 2001; Guermonprez et al, 2002).
One new candidate to modulate DC^T cell interaction is the
recently described cytokine interleukin (IL)-21, whose expression
is restricted toT cells (Parrish-Novak et al, 2000). IL-21 is a mem-
ber of the four-helix bundle family and has high structural
similarities with IL-15. Like IL-15, IL-21 binds to its private
high-a⁄nity receptor chain and to the common g-chain (Asao
et al, 2001). This functional heterodimeric IL-21 receptor (IL-
21R) has been shown to be expressed by T, B, and NK cells so
far (Parrish-Novak et al, 2000).
These observations raise the possibility that IL-21 is involved
in T cell-dependent immune responses mediated by professional
antigen-presenting cells like DC. Here we have explored this hy-
pothesis in vitro, using coculture of DC with antigen-speci¢c
CD8þ T cells and in vivo by active sensitization using hapten-
labeled, in vitro-generated DC to induce a contact hypersensitivity
(CHS) response in mice. Apart from being the experimental
counterpart for a variety of dermatologic disorders of great clin-
ical relevance (Grabbe and Schwarz, 1998), the study of CHS
responses provides a unique approach to assess multiple functions
of DC in vivo, where the overall T cell-mediated CHS response
represents the net result of both the antigen-presenting and the
T cell-activating functions of DC at multiple stages.
To study the e¡ects of IL-21 on DC-mediated induction of T
cell priming, we incubated DC with IL-21 before in vitro/in vivo
use. IL-15, which is in contrast to IL-21 produced by DC itself
and which mediates their activation (Mattei et al, 2001), was used
for comparison. We show here that DC express the complete
IL-21 receptor and that IL-21 has the potential to inhibit DC-
induced antigen-speci¢c, but not unspeci¢c,T cell activation and
di¡erentiation in vitro and in vivo.
MATERIALS ANDMETHODS
Mice C57BL/6 mice were purchased from Charles River. OTItg mice,
transgenic for a CD8þ restricted TCR-recognizing OVA(257^264) peptide
were provided by A. von Bonin (BNI, Hamburg, Germany). All mice
were used at 8 to 10 wk and were maintained in pathogen-free conditions.
In vivo experiments were performed in compliance with national and
institutional guidelines.
DC preparation Bone marrow-derived DC were generated as
previously described (Lutz et al, 1999). On day 8, cells were harvested and
analyzed further. Purity was routinely495% CD11cþ DC as determined
by FACS analysis.
RT-PCR Total RNAwas extracted from 5106 cells after 8 d of culture
using RNAzol (Life Technologies, Gaithersburg, MD) following the
manufacturer’s instructions. cDNA was synthesized using random
hexanucleotide primers and the Superscript preampli¢cation system II
(Life Technologies).
Primer sequences Primer sequence were as follows: IL-21R sense
50 -CTCAGCCAGGCACTTCATTCAGG-30 and IL-21R antisense 50 -
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ATCACAGGAAGGGCATTTAGC-30; IL-15Ra sense 50 -AACATCCACC
CTGATTGAGTGT-30 and IL-15Ra antisense 50 -GTTTCCATGGTTTCC
ACCTCAA-30; gc sense 50 -GTCGACAGAGCAAGCACCATGTTGAAA
CTA-30 and gc antisense 50 -GGATCCTGGGATCACAAGATTCTGTAG
GTT-30; and b-actin sense 50 -GTGGGGCGCCCCAGGCACCA-30 and
b-actin antisense 50 -CTCCTTAATGTCACGCACGATTTC-30 (all from
Metabion, Lexington, KY). To exclude contaminations, all experiments
were run with a mock PCR. b-Actin message was used to normalize
cDNA amount.
Proliferation assays T cells were isolated from lymph nodes (LN) of
OTI TCR-transgenic mice. DC were labeled with 2 mg OVA(257^264)
peptide and IL-15 or IL-21 (100 ng/mL, Tebu-Bio, O¡enbach, Germany;
and Zymogenetics, Seattle,WA, respectively) for 2 h at 371C in 500 mL of
RPMI, washed, and plated with six replicates into 96-well plates (Greiner,
Longwood, FL) at 1104 cells per well along with increasing amounts of
lymph node cells (6.25104^1105). In an additional setup, an anti-IL-21
antibody (5 mg/mL, R&D Systems, Minneapolis, MN) was added to the
culture. After 48 h, cells were pulsed for 18 h with 0.2 mCi per well
[3H]thymidine, and proliferation was analyzed by liquid scintillation
counting (Wallac/Perkin-Elmer, Boston, MA). A mixed leukocyte
reaction was set up by incubating the DC from C57BL/6 mice and lymph
node cells from BALB/c mice (1104^1106 cells) for 5 d, and
proliferation was assessed as above.
CHS to £uorescein 5-isothiocyanate (FITC) To estimate the capacity
of DC to induce antigen-speci¢c T cell sensitization in vivo, bone marrow-
derived DC (1106 cells/mL) from C57BL/6 mice were incubated for 2 h
with 20 ng per mL IL-21 (ZymoGenetics) or IL-15 (Tebu-Bio) at 371C and
were labeled during the last 30 min with FITC (Sigma Chemical Co., St.
Louis, MO) as described (Macatonia et al, 1986). DC were washed
and injected in one footpad with a Hamilton syringe (5105 cells in
50 mL phosphate-bu¡ered saline). After 5 d, mice were challenged using
50 mL of FITC in acetone:dibutylphthalate (1:1, Sigma Chemical Co.)
(Macatonia et al, 1986) on the right ear. The left ear was painted with the
diluent as control. In addition, unsensitized mice were painted with FITC.
The CHS response was determined by measuring ear swelling at 24 h after
challenge using a micrometer (Mitutoyo, Aurora, IL). A second injection of
FITC-labeled DC (without any cytokine incubation) was performed 14 d
after ¢rst injection. Mice were challenged on the left ear 5 d after the
second injection (day 19) and swelling was measured 24 h later.
Statistical analysis Results are presented as means7SD from data of
two to three experiments (using a total of 8^12 mice/group). PCR data
from one representative experiment are shown. A Student’s t test for
unpaired samples was used for the determination of statistical di¡erences
(pp0.05; pp0.01).
RESULTS AND DISCUSSION
The principal method to generate DC in vitro was adapted in our
laboratory from a previous publication (Lutz et al, 1999) to yield in
high amounts of pure, CD11cþ DC. Expression of the IL-21R
and the high-a⁄nity IL-15Rawas analyzed by PCR. DC express
the complete IL-21R message, which consists of the common g-
chain and a private IL-21R under unstimulated conditions (Fig 1,
¢rst column). These products are not upregulated by the strong
DC stimulus lipopolysaccharide (Fig 1, second column). As pre-
viously reported (Mattei et al, 2001), the high-a⁄nity IL-15Ra is
expressed weakly in unstimulated DC but is upregulated upon
lipopolysaccharide stimulation (Fig 1). To validate the biologic
function of the IL-21R, we veri¢ed the uptake of IL-21 into
DC by confocal microscopy after 30 min of incubation with IL-
21 (not shown). These data revealed that murine DC express a
functional receptor for the newly described cytokine IL-21.
To estimate the function of IL-21 during DC^T cell interac-
tion we ¢rst studied its e¡ects on T-cell activation mediated by
DC in vitro. To this purpose we used OVA peptide-speci¢c, trans-
genic CD8þ T cells. The e¡ects of IL-21 were compared to the
structural homolog IL-15. First, DC were pulsed for 2 h with
OVA peptide alone, or additionally IL-15 or IL-21 were added
in parallel to OVA peptide. After being washed, T cells from
lymph nodes of OTI mice, expressing the CD8þ T cell-re-
stricted, transgenic T cell receptor, which speci¢cally recognizes
OVA peptide, were given to the peptide/cytokine-labeled DC.
As depicted in Fig 2A, OVA peptide-labeled DC induced a
strong, antigen-speci¢c T cell proliferation. Strikingly only 2 h
of DC stimulation with IL-21 high signi¢cantly suppressed the
DC-mediated CD8þ T cell proliferation (Fig 2A, IL-21). Addi-
tion of IL-10, which has recently been identi¢ed as an important
Figure1. DC express the common c-chain and high-a⁄nity IL-
21/-15 receptor subunits. DCwere generated for 8 d and stimulated with
10 ng per mL lipopolysaccharide for 24 h or left unstimulated (medium).
Figure 2. IL-21 reduces antigen-speci¢c CD8þ T cell proliferation
but not mixed leukocyte reaction in vitro. (A) DC were incubated in
parallel to OVA(257^264) peptide with IL-15 or IL-21 for 2 h. To neutralize
the e¡ects of T cell-secreted IL-21, anti-IL-21 antibodies were added to the
culture. Peptide-speci¢c, transgenic T cells were added for an additional 72
h. T cell proliferation was estimated by [3H]thymidine uptake. The experi-
ment was repeated twice with six replicates for each experiment; shown is
the median7SD. Signi¢cance was calculated using Student’s t test
(pp0.01; pp0.05). CPM, counts per minute. (B) DC generated from
C57BL/6 mice were incubated with allogenic T cells from BALB/c mice:
DC were labeled with cytokines as described above. After 72 h, prolifera-
tion was assessed through [3H]thymidine incorporation.
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inhibitory cytokine for DC activation (Mˇller et al, 2002), could
not further suppress T-cell proliferation compared to IL-21 in this
assay (not shown). Interestingly, using a high number of T cells
(100,000) strongly inhibited the proliferation of T cells under all
conditions, probably due to a T cell-secreted factor (Fig 2A). Be-
causeTcell-derived IL-21 obviously inhibited the antigen-speci¢c
DC-induced T cell proliferation, a blocking anti-IL-21 antibody
was added to the culture and could signi¢cantly enhance the
T cell proliferation in this assay (Fig 2A, right panel, þ a
-IL-21).
This adds new aspects to the role of IL-21. In the human sys-
tem, it has been shown that IL-21 can enhance proliferation of
a-CD3 stimulated T cells and IL-15-stimulated NK cells in vitro;
nevertheless, it rather inhibits expansion of murine NK cells, sug-
gesting species-speci¢c di¡erences of IL-21 action. Nevertheless,
during the complex process of T cell activation by murine DC
IL-21 obviously inhibits T cell priming and DC maturation,
which could also be observed using human DC (T. Musso and
S. Bulfone-Paus, unpublished observations).
In contrast to the antigen-speci¢c reaction, IL-21-preincu-
bated DC did not reduceTcell proliferation after unspeci¢c allor-
ecognition in a mixed leukocyte reaction (Fig 2B). These data
support the fact that IL-21 is likely an important regulator of ac-
quired immune responses rather than it could in£uence innate
immune reactions. This notion is also promoted by our ¢ndings
in which IL-21 also inhibits functions related to antigen presenta-
tion in macrophages (K. Brandt and R. Rˇckert, unpublished
data).
These results prompted us to test whether blocking of DC-
mediated, speci¢c T cell reactions by short-time addition of IL-
21 is also relevant during CHS in vivo, using a well-established
model of FITC-induced murine CHS response. DC were incu-
bated with IL-15 and IL-21 for 2 h and in parallel labeled with
the hapten FITC and injected in the hind footpad of syngenic
mice as previously described (Macatonia et al, 1986). After 5 d,
mice were challenged by applying 50 mL of FITC on the dorsal
and ventral sides of the right ear, and ear swelling was measured
at indicated time points.
As expected (Macatonia et al, 1986), injection of FITC-labeled
DC resulted ‘‘after FITC-challenge’’ in a profound ear swelling.
Incubation with IL-15 for 2 h failed to further elevate the induc-
tion of this T cell-mediated CHS response compared to DC
(Fig 3A).
In contrast, IL-21 incubation of the DC for only 2 h before in-
jection completely abrogated the capacity of these DC to induce
an antigen-speci¢c type IV immune response in vivo, and the
FITC-induced ear swelling did not even exceed that of the non-
immunized controls (Fig 3A). To con¢rm the fact that the sensi-
tization was based on active migration of the injected, viable DC
from the footpad to the draining lymph nodes, control mice were
injected with FITC-labeled glutaraldehyde ¢xed (i.e., dead) DC
(Eggert et al, 1999), which failed to induce any CHS response
(not shown). Therefore, the absent T cell stimulatory capacity of
IL-21-treated DC is most likely attributed to their low immuno-
genic phenotype and not due to a homing defect (i.e., migration
to the draining lymph nodes). To exclude the fact that the DC
simply undergo cell death after IL-21 stimulation, we incubated
themwith IL-21 from 1 to 200 ng per mL and analyzed apoptosis
by annexin V/propidium iodide staining using FACS. Neverthe-
less, neither IL-15 nor IL-21 induced apoptosis above the levels of
DC cultured in medium (data not shown). Cells were also evalu-
ated by morphologic criteria using microscopy and FACS, reveal-
ing no di¡erences after short-time incubation with IL-21. These
e¡ects and the intact migration of DC to dendritic lymph node
cells suggest that IL-21 mediates a speci¢c, suppressive e¡ect on
DC-induced antigen-speci¢c immune reactions rather than lead-
ing to a ‘‘null event.’’
To further analyze whether IL-21-treated DC induce a state of
antigen-speci¢c unresponsiveness, mice that had been injected
with the cytokine-primed (DCþ IL-15; DCþ IL-21), FITC-la-
beled DC were injected 14 d later again with FITC-labeled, but
not cytokine-incubated, DC. Interestingly, injecting DC in pre-
vious DCþ IL-21-sensitized mice failed to induce an ear swel-
ling above control levels (Fig 3B). In contrast, mice that had
been treated with DCþ IL-15 and 14 d later with DC, mounted
a signi¢cantly enhanced ear swelling compared to mice sensitized
twice with DC.
Taken together, our data imply that mice sensitized with IL-
21-labeled DC are unable to establish antigen-speci¢c responses.
Whether this is due to the induction of regulatory T cells or to
the inability of IL-21-treated DC to instruct memoryT cells has
not been clear until now. In this regard, previous reports pointed
out that IL-21 inhibits the IL-15-mediated proliferation of mur-
ine CD8þ memory T cells and the subsequent upregulation of
cytokine receptors for IL-2, IL-15, and IFN-g (Parrish-Novak
et al, 2002), which could also be an explanation for the suppressive
e¡ects of IL-21 in our experiments. It is also reasonable to spec-
ulate that fromTcells released IL-21 (during or after contact with
antigen-presenting DC) may inhibit activation and expression of
costimulatory signals, thereby providing a negative feedback sig-
nal keeping DC in an immature, low immunogenic state. Subse-
quently antigen presentation by these immature DC might
induce di¡erentiation of na|«ve T cells toward suppressor/regula-
tory phenotype.
Other cytokines in the extracellular environment, notably from
T cell-released IL-10, have been implicated in impeding DC ma-
turation, resulting in the retention of an ‘‘immature’’ phenotype,
which was recently demonstrated also for DC-mediated in vivo re-
actions (Mˇller et al, 2002). Thus, we show here for the ¢rst time
that the newly described cytokine IL-21 has comparable inhibi-
tory e¡ects on DC-inducedT-cell activation like IL-10.This makes
IL-21R-mediated signaling an intriguing novel target for the
pharmacologic manipulation of clinically relevant CHS responses.
Taken together we showed for the ¢rst time that short-time
incubation of DC with IL-21was able to abrogate antigen-speci-
¢c T cell responses in vitro and in vivo.
Figure 3. Short-time IL-21 labeling blocks CHS induction by DC.
(A) DC were incubated with IL-15 and IL-21 for 2 h and in parallel labeled
with the hapten FITC. A total of 5105 DC were injected in the hind
footpad of C57BL/6 mice (day 1). Five days later, mice were challenged on
the right ear, and swelling was measured after 24 h. As control, one ear was
painted with diluent and unsensitized mice were challenged with FITC.
Signi¢cance was calculated between DC and DCþ IL-21 using Student’s t
test (pp0.01). (B) A second injection of FITC-labeled DC was per-
formed at day 14 after ¢rst injection. Mice were challenged on the left ear
5 d after the second injection (day 19) and swelling was measured 24 h later.
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